Inj mosunetuzumab-axgb, 1 mg
Products billed under this code include Lunsumio, Lunsumio Velo.
Payment limit per 1 MG, by effective quarter, 4Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9350
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Lunsumio | Genentech, Inc. | 50242-0142-01 | 30 | $20,294.52 |
| Lunsumio | Genentech, Inc. | 50242-0159-01 | 1 | $676.484 |
| Lunsumio Velo | Genentech, Inc. | 50242-0177-01 | 5 | $3,382.42 |
| Lunsumio Velo | Genentech, Inc. | 50242-0201-01 | 45 | $30,441.78 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $676.484 | +$1.989 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $674.495 | +$19.953 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $654.542 | −$0.837 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $655.379 | +$0.75 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $654.629 | +$1.883 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $652.746 | +$11.79 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $640.956 | −$0.111 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $641.067 | +$5.602 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $635.465 | −$1.728 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $637.193 | +$8.046 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $629.147 | −$0.488 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $629.635 | −$0.068 | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $629.703 | – | 1 MG | Inj mosunetuzumab-axgb, 1 mg | v1, posted October 10, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026
- 1Q25: 2025-12-19_january-2025-asp-pricing-file-03-11-25-final-file.zipposted December 19, 2025
- 4Q24: 2025-06-11_october-2024-asp-pricing-file.zipposted June 11, 2025
- 3Q24: 2025-06-11_july-2024-asp-pricing-file.zipposted June 11, 2025
- 2Q24: 2025-03-11_april-2024-asp-pricing-file.zipposted March 11, 2025
- 1Q24: 2024-12-19_january-2024-asp-pricing-file.zipposted December 19, 2024
- 4Q23: 2024-10-10_october-2023-asp-pricing-file.zipposted October 10, 2024